Please use this identifier to cite or link to this item:
http://repository.unizik.edu.ng/handle/123456789/536
Title: | Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm |
Authors: | Abubakar, Abdullahi Rabiu Ahmad, Rahnuma Rowaiye, Adekunle Babajide Rahman, Sayeeda Iskandar, Katia Dutta, Siddhartha Oli, Angus Nnamdi Dhingra, Sameer Tor, Maryam Abba Etando, Ayukafangha Kumar, Santosh Irfan, Mohammed Gowere, Marshall Chowdhury, Kona Akter, Farhana Jahan, Dilshad Schellack, Natalie Haque, Mainul |
Keywords: | cytokine storm SARS-CoV-2 COVID-19 pathogenesis immune response interleukins hyperinflammation |
Issue Date: | 25-Mar-2022 |
Publisher: | Multidisciplinary Digital Publishing Institute |
Citation: | Life, 12, 478. |
Abstract: | COVID-19-infected patients require an intact immune system to suppress viral replication and prevent complications. However, the complications of SARS-CoV-2 infection that led to death were linked to the overproduction of proinflammatory cytokines known as cytokine storm syndrome. This article reported the various checkpoints targeted to manage the SARS-CoV-2-induced cytokine storm. The literature search was carried out using PubMed, Embase, MEDLINE, and China National Knowledge Infrastructure (CNKI) databases. Journal articles that discussed SARS-CoV-2 infection and cytokine storm were retrieved and appraised. Specific checkpoints identified in managing SARS-CoV-2 induced cytokine storm include a decrease in the level of Nod-Like Receptor 3 (NLRP3) inflammasome where drugs such as quercetin and anakinra were effective. Janus kinase-2 and signal transducer and activator of transcription-1 (JAK2/STAT1) signaling pathways were blocked by medicines such as tocilizumab, baricitinib, and quercetin. In addition, inhibition of interleukin (IL)-6 with dexamethasone, tocilizumab, and sarilumab effectively treats cytokine storm and significantlyreduces mortality caused by COVID-19. Blockade of IL-1 with drugs such as canakinumab and anakinra, and inhibition of Bruton tyrosine kinase (BTK) with zanubrutinib and ibrutinib was also beneficial. These agents' overall mechanisms of action involve a decrease in circulating proinflammatory chemokines and cytokines and or blockade of their receptors. Consequently, the actions of these drugs significantly improve respiration and raise lymphocyte count and PaO2/FiO 2ratio.Targeting cytokine storms' pathogenesis genetic and molecular apparatus will substantially enhance lung function and reduce mortality due to the COVID-19 pandemic. |
Description: | Scholarly Work |
URI: | https://doi.org/10.3390/life12040478 http://repository.unizik.edu.ng/handle/123456789/536 |
Appears in Collections: | Scholarly Works |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
OLI ANGUS NNAMDI 18.pdf | 3.65 MB | Adobe PDF | View/Open |
Items in UnizikSpace are protected by copyright, with all rights reserved, unless otherwise indicated.